[1] Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldo-keto reductase superfamily [J]. Biochem Pharmacol, 1997, 54(6):639-647. [2] Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy [J]. Nat Med, 2013, 19(5): 619-625. [3] Liu C, Lou W, Zhu Y, et al. Intracrine androgens and akr1c3 activation confer resistance to enzalutamide in prostate cancer [J]. Cancer Res, 2015, 75(7) : 1413-1422. [4] Penning TM, Drury JE. Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms [J]. Arch Biochem Biophys, 2007, 464(2):241-250. [5] Penning TM. The aldo-keto reductases (AKRs): Overview [J]. Chem Biol Interact, 2015, 234: 236-246. [6] Hyndman D, Bauman DR, Heredia VV, et al.The aldo-keto reductase superfamily homepage [J]. Chem Biol Interact, 2003, 143-144:621-631. [7] Dhagat U, Endo S, Sumii R, et al. Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid [J]. J Med Chem, 2008, 51(15):4844-4848. [8] Bartosz AF, Dawid M, Maciej BW, et al. Transcript level of AKR1C3 is down-regulated in gastric cancer [J]. Biochem Cell Biol, 2016, 94(2):138-146. [9] Nakarai C, Osawa K, Akiyama M, et al. Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer [J]. Clin Exp Med, 2015, 15(3):333-341. [10] Zhao SF, Wang SG, Zhao ZY, et al. AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies [J]. Oncol Lett, 2019, 18(5):4515-4522. [11] Zakharov V, Lin HK, Azzarello J, et al. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma [J]. Int J Clin Exp Pathol, 2010, 3(6):608-617. [12] Wang B, Gu Y, Hui K, et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling [J].Urol Oncol, 2018, 36(10):472.e11-472.e20. [13] Xie L, Yu J, Guo W, et al. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer [J]. Cancer Gene Ther, 2013, 20(4):260-266. [14] Tiryakioglu NO, Tunali NE. Association of AKR1C3 polymorphisms with bladder cancer [J]. Urol J, 2016, 13(2):2615-2621. [15] Li X, Hong X, Gao X, et al. Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3 [J]. Cancer Manag Res, 2018, 10:3149-3158. [16] Zhong T, Xu F, Xu J, et al .Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss [J]. Biomed Pharmacother, 2015, 69:317-325. |